Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post Marketing Observational Study to Assess Quality of Life Changes in Swedish Patients With Moderate or Severe Hidradenitis Suppurativa (HS) After 6 Months on Adalimumab Treatment (HOPE Study)

NCT02739828 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02739828
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02739828 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post Marketing Observational Study to Assess Quality of Life Changes in Swedish Patients With Moderate or Severe Hidradenitis Suppurativa (HS) After 6 Months on Adalimumab Treatment (HOPE Study)
Lead sponsor
AbbVie
Phase
Observational
Overall status
Completed
Start date
April 7, 2016
Completion date
March 28, 2018
Enrollment
24 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis suppurativa